Allergan (AGN) in Focus: Stock Moves 6.2% Higher

Allergan plc was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $115.73 –$139.51 in the past one-month time frame, witnessed a sharp increase yesterday.

The company's Zacks Consensus Estimate for the current quarter has moved higher over the past few weeks, suggesting that more solid trading could be ahead for Tailored Brands. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Allergan currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Allergan plc Price

Investors interested in the Medical – Genetics Drugs industry may consider Adamas Pharmaceuticals, Inc. , which has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is AGN going up? Or down? Predict to see what others think:Up or Down

Will you retire a millionaire?

 

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”

 

Click to get it free >>

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>


No ad available